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Motivation  for  visualizing  treatment  rankings  
The  number  of  published  network  meta-­analysis  (NMA)  reports  has  increased  substantially  in  recent  
years.  NMAs  combine  “direct”  and  “indirect”  evidence  and  enable  comparisons  between  all  relevant  
treatment  options  for  a  given  disease,  even  when  some  treatments  have  not  been  directly  compared  
with  each  other.  In  the  absence  of  randomized  trials  comparing  all  treatment  options  to  each  other,  
NMAs  address  important  information  needs  of  patients  and  clinicians  about  the  comparative  
effectiveness  of  treatment  alternatives.    
   NMA  results  may  be  difficult  to  communicate  and  interpret  effectively  given  the  large  volume  of  
complex  information  generated  on  multiple  alternative  treatments  with  multiple  benefit  and  harm  
outcomes.  For  example,  NMA  comparing  5  treatments  result  in  10  pair-­wise  comparisons;;  if  results  are  
available  for  3  benefit  and  3  harm  outcomes,  decision  makers  are  faced  with  60  sets  of  results.  
Identifying  the  ‘best’  treatment  option  to  initiate  therapy  is  thus  not  straightforward.  Although  several  
graphical  and  tabular  displays  exist  to  report  the  pertinent  results  of  NMAs,  existing  reporting  guidelines  
differ  in  their  recommendations.  Consequently,  there  is  significant  variation  in  the  current  way  NMA  
findings  are  reported  and  presented.    
   A  key  strength  of  NMAs  is  the  ability  to  rank  treatments.  However,  such  rankings  are  specific  to  
individual  outcomes  and  often  change  significantly  across  different  benefit  and  harm  endpoints.  For  
example,  a  treatment  that  performs  well  in  prolonging  survival  may  fare  unfavorably  in  terms  of  
increasing  the  likelihood  of  side  effects.  Combining  the  relative  performance  of  different  treatments  on  
multiple  outcomes  remains  a  challenge.    
   One  option  for  generating  a  single  coherent  ranking  of  treatments  is  to  quantitatively  combine  
NMA  findings  with  patient  preferences  [1].  Preference  information  captures  the  relative  importance  of  
attributes  that  differ  among  alternative  treatments.  For  example,  a  patient  near  the  end  of  life  may  
prefer  a  therapeutic  strategy  that  minimizes  drug-­related  side  effects  (however  minor),  even  if  the  
therapy  has  less  potential  for  prolonging  survival  than  its  alternatives.  In  such  a  scenario,  survival  
endpoints  would  carry  less  weight  than  adverse  outcomes,  favoring  the  treatments  that  have  superior  
side  effect  profiles.  Combination  of  NMA  findings  with  preference  information  would  allow  for  generating  
and  communicating  a  coherent  ranking  of  all  treatment  alternatives.    
  
Statin  Ranking  Tool     
A  recent  series  of  NMAs  evaluated  the  comparative  benefits  and  harms  of  widely  popular  cholesterol-­
lowering  medications,  statins,  on  the  basis  of  a  systematically  identified  set  of  randomized  trials  
published  since  1990  [2-­4].  While  some  statins  performed  well  in  terms  of  benefit  outcomes  (measured  
in  terms  of  reducing  the  risk  of  all-­cause  mortality,  coronary  and  cerebrovascular  events)  [2,3],  others  
had  relatively  favorable  side  effect  profiles  (measured  in  terms  of  increasing  the  risk  of  experiencing  
creatine  kinase  elevations,  transaminase  elevations,  myalgia,  and  treatment  discontinuations  due  to  
other  adverse  events)  [4].  These  analyses  did  not  identify  a  single  statin  that  outperformed  its  
comparators  in  terms  of  both  benefit  and  harm  outcomes.    
   Data  visualization  offers  an  opportunity  to  communicate  the  top-­level  findings  of  these  detailed  
analyses.  The  Statin  Ranking  Tool  (available  at  http://lse.live.kiln.digital/statins/)  uses  a  visually  
appealing,  intuitive,  and  easy-­to-­navigate  interactive  interface  to  summarize  the  key  findings  of  several  
published  NMAs  comparing  the  effectiveness  of  individual  statins  on  three  benefit  and  four  harm  
outcomes.  Focusing  on  five  of  the  most  commonly  used  statins  (atorvastatin,  lovastatin,  pravastatin,  
rosuvastatin,  simvastatin),  it  excludes  fluvastatin  (rarely  used  in  clinical  practice)  and  pitavastatin  
(previous  network  meta-­analyses  did  not  consider  its  effect  on  mortality,  coronary,  and  cerebrovascular  
events)  [2,3].  This  tool  was  developed  as  part  of  the  London  School  of  Economics  and  Political  Science  
Institute  of  Public  Affairs  data  visualization  project,  which  aims  to  make  academic  research  visible  and  
accessible  to  the  wider  public.    
   The  Statin  Ranking  Tool  has  two  data  visualization  features.  The  first  feature  presents  the  
previously  published  rankings  of  individual  statins  on  seven  outcomes,  both  separately  and  in  
combination  with  each  other  (Figure  1).  Treatment  rankings  are  expressed  as  probabilities  (adding  up  
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to  one  for  each  statin  and  for  each  rank)  and  reflect  the  estimated  effect  sizes  obtained  from  NMAs.  As  
described  previously  [5],  the  surface  under  the  cumulative  ranking  line  (also  known  as  SUCRA)  for  
each  treatment  provides  a  numerical  summary  of  the  overall  performance  of  each  statin  on  each  
outcome  (1.0  when  a  statin  is  certain  to  the  best  and  0.0  when  it  is  certain  to  be  the  worst),  taking  into  
account  not  only  the  magnitude  of  the  effect  but  also  the  uncertainty  around  it.    
   The  novel  aspect  of  the  tool  is  its  interactive  web-­based  interface,  which  allows  the  users  to  
focus  on  individual  benefit  and  harm  outcomes  and  see  how  different  statins  perform  on  each  endpoint.  
In  addition,  the  tool  allows  the  users  to  specify  the  relative  importance  of  multiple  outcomes.  The  
visualization  is  dynamic  and  reinforces  the  most  critical  ‘gist’  message  of  the  NMA  findings:  how  the  
rankings  of  individual  statins  change  as  users  modify  the  weights  applied  to  different  benefit  and  harm  
outcomes  (from  ‘not  important’  to  ‘very  important’).  The  tool  quantitatively  incorporates  individual  
preferences  by  multiplying  weights  applied  to  different  outcomes  by  the  performance  of  different  statins  
on  different  outcomes  (as  obtained  from  the  NMA).  The  computation  of  overall  rankings  is  therefore  
straightforward:  SUCRA  scores  are  multiplied  by  the  normalized  weights  specified  by  the  user  (i.e.,  
weights  applied  to  different  outcomes  add  up  to  one).    
   The  second  key  feature  of  the  Statin  Ranking  Tool  is  an  interactive  network  diagram,  which  
presents  the  evolution  of  the  evidence  base  on  statins  from  1990  to  2010  (Figure  2).  The  dynamic  
network  diagram  maps  the  existing  comparisons  of  statins  to  each  other,  and  depicts  the  entirety  of  the  
randomized  trial  data  on  this  extensively  researched,  popular,  and  widely  used  classes  of  drugs.    
Given  its  web-­based  interface,  both  data  visualization  features  of  the  Statin  Ranking  Tool  have  
the  potential  to  be  continually  updated  and  improved  as  more  information  becomes  available.  
Accordingly,  this  approach  can  serve  as  a  reporting  companion  to  ‘living’  systematic  reviews  and  NMAs.    
  
Limitations  and  Future  Directions  
Treatment  rankings  presented  in  the  Statin  Ranking  Tool  share  the  limitations  of  the  evidence  base.  
Randomized  trials  included  in  the  network  meta-­analyses  differ  in  terms  of  their  size,  risk-­of-­bias,  and  
external  validity.  Despite  their  limitations,  these  analyses  offer  the  most  comprehensive  picture  of  how  
different  statins  compare  to  each  other.      
Treatment  rankings  in  terms  of  rankograms  and  SUCRAs  should  not  be  interpreted  in  isolation  
from  the  relative  treatment  effect  estimates  on  which  they  are  based  (i.e.,  odds  ratios,  relative  risks,  and  
their  95%  uncertainty  intervals).  Recent  empirical  evaluations  have  suggested  that  treatment  rankings  
may  not  be  statistically  precise  [6].  In  addition,  rankograms  and  SUCRAs  pose  challenges  for  
interpretation:  they  are  not  intuitive  measures  of  effect  and  may  not  be  clinically  meaningful.  Future  
applications  of  data  visualization  should  consider  incorporating  additional  information  to  help  users  
effectively  interpret  the  ranking  information.  This  could  include  easy-­to-­understand  visual  summaries  of  
absolute  treatment  effects  using  either  bar  charts  or  pictographs.    
In  the  current  Statin  Ranking  Tool,  the  overall  ranking  for  each  statin  is  a  simple  weighted  
average  of  its  performance  on  different  outcomes  with  the  weight  specified  directly  by  the  user  (by  
moving  the  cursor  from  ‘not  important’  to  ‘very  important’).  There  are  several  opportunities  to  develop  a  
more  sophisticated  ranking  machinery.  For  example,  the  tool  does  not  specify  what  ‘very  important’  and  
‘not  important’  ends  of  the  spectrum  mean  for  each  outcome.  Accordingly,  weighting  the  relative  
importance  of  different  outcomes  may  be  a  challenging  task:  the  tool  neither  considers  nor  
demonstrates  how  the  application  of  different  weights  would  change  the  number  of  side  effect  episodes  
traded-­off  to  prevent  one  major  clinical  event,  or  vice  versa.    
One  opportunity  is  to  formally  combine  NMA  and  multi-­criteria  decision  analysis  (MCDA)[2].  
MCDA  is  an  established  framework  for  making  complex  decisions  such  as  choosing  among  multiple  
options  by  trading  off  several  positive  and  negative  outcomes.  Quantitative  implementation  of  MCDA  
with  NMA  could  serve  as  a  basis  for  a  treatment  selection  platform  that  could  incorporate  future  NMAs  
as  they  become  available.  For  example,  an  automated,  freely  available  web-­based  tool  could  enable  
application  of  this  combined  method  to  any  given  treatment  selection  problem.        
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Conclusion  
The  Statin  Ranking  Tool  offers  a  proof-­of-­concept  novel  approach  to  data  visualization  and  summarizes  
an  extensive  body  of  literature  previously  synthesized  in  a  series  of  NMAs.  Methodological  advances  
will  further  improve  the  ranking  machinery  behind  the  tool  and  enable  its  applicability  to  a  wide  range  of  
treatment  selection  decisions  informed  by  NMAs.    
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Figure  1.  Overall  ranking  of  individual  statins  from  best  to  worst  by  combining  network  meta-­analysis  
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Legend:  The  interactive  Statin  Ranking  Tool  shows  the  overall  ranking  of  five  statins  from  best  to  worst  
in  terms  of  three  benefit  (all-­cause  mortality,  coronary  events,  cerebrovascular  events)  and  four  harm  
outcomes  (muscle  pain,  kidney  enzyme  elevations,  liver  enzyme  elevations,  discontinuations  due  to  
other  adverse  events).  Users  can  specify  the  relative  importance  of  different  outcomes  by  moving  the  
cursors  from  ‘not  important’  to  ‘very  important’.  Different  colors  correspond  to  different  outcomes  and  
the  bars  correspond  to  the  relative  weight  put  on  each  outcome.  The  data  visualization  is  dynamic  and  
the  overall  ranking  of  individual  statins  changes  depending  on  user  preferences.  For  example,  (a)  
simvastatin  ranks  as  the  best  option  when  the  user  specifies  that  all-­cause  mortality  is  the  only  
important  outcome;;  (b)  pravastatin  is  the  best  treatment  option  when  the  user  specifies  kidney  enzyme  
elevations  as  the  only  important  outcome;;  and  (c)  simvastatin  ranks  best  when  the  user  considers  all-­
cause  mortality  to  be  the  most  important  outcome  followed  by  coronary  events  and  cerebrovascular  
events,  which  are  in  turn  more  important  than  all  harm  endpoints.       
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Legend:  The  nodes  in  these  network  diagrams  show  different  statin  drugs  and  the  lines  connecting  the  
nodes  show  the  head-­to-­head  randomized  controlled  trials  directly  comparing  two  drugs  to  each  other.  
The  size  of  the  nodes  is  proportional  to  the  number  of  participants  receiving  a  given  cholesterol-­
lowering  drug  and  the  thickness  of  the  lines  connecting  the  nodes  is  proportional  to  the  number  of  
clinical  trials  comparing  two  drugs  to  each  other.  The  network  diagrams  are  dynamic:  using  the  cursor  
at  the  bottom  of  each  diagram,  users  can  view  the  evolution  of  the  evidence  base  over  time,  from  1990  
to  (a)  1995,  (b)  2000,  (c)  2005,  and  (d)  2010.    
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